ClinicalTrials.gg
CompletedNCT03574545Updated Dec 2, 2025

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

A Phase 1 interventional study of ianalumab in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Enrollment
26th of 30
48 · median 98
Started
2018
the only one that year
Phase 1
7 of 30
1 open now
Registered
26th of 30
by date

Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 26th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 1, and was the 26th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

This study will assess the safety and pharmacokinetic comparability of two VAY736 drug products in patients with rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • VAY736
  • Ianalumab
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfill 2010 ACR/EULAR criteria for RA Aletaha et al 2010 at Screening
  • Active disease defined as ≥ 2 swollen joints (of 58 evaluable joints) and ≥ 2 tender joints (of 60 evaluable joints) despite stable MTX ≤ 25 mg/week and/or hydroxychloroquine ≤ 400 mg/day treatment for at least 2 months prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Prior or previous use of (specific dosages and intervals prior to study start may apply): other drugs, B-cell depleting therapy (e.g. rituximab), monoclonal antibodies (mAb), i.v. / s.c. Ig, thymoglobulin, i.v. or oral cyclophosphamide, oral cyclosporine, soluble cytokine receptors, azathioprine.
  • Currently receiving prednisone >10 mg/day (or equivalent oral ) or dose adjustment within 2 weeks prior to randomization
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or enrollment, or history of recurrent infection or of bacterial infections with encapsulated organisms
  • Receipt of live/attenuated vaccine within a 2-month period before randomization
  • Pregnant or nursing (lactating) women
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of from screening and for 4 months after stopping of investigational drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Reference VAY736 Drug Product

    Powder for solution for injection / infusion

    Biological: ianalumab

  • Experimental
    Test VAY736 Drug Product

    Solution for injection

    Biological: ianalumab

Interventions

  • Biologicalianalumab

    Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)

    Also known as: VAY736

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as measured by the number of patients with adverse events

    The number of patients with adverse events after repeated subcutaneous (s.c) injections of a fixed dose of ianalumab

    Time frame: Week 0 - 112

  2. Pharmacokinetic comparability at steady state - AUCtau

    The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)

    Time frame: Week 8 - 12

  3. Pharmacokinetic comparability at steady state - Cmax

    Observed maximum serum concentration of ianalumab following drug administration (Cmax)

    Time frame: Week 8 - 12

Secondary outcomes

  1. Pharmacokinetic comparability after the first dose - AUCtau

    The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)

    Time frame: Week 0 - 4

  2. Pharmacokinetic comparability after the first dose - Cmax

    Observed maximum serum concentration of ianalumab following drug administration (Cmax)

    Time frame: Week 0 - 4

  3. Pharmacokinetic comparability after the first dose - Tmax

    Time to reach the maximum concentration after drug administration (Tmax)

    Time frame: Week 0 - 4

  4. Pharmacokinetic comparability of two ianalumab drug products after the last dose - AUCinf

    The area under the serum ianalumab concentration-time curve from time zero to infinity (AUCinf)

    Time frame: Week 8 - 12

  5. Pharmacokinetic comparability after the last dose - Tmax

    Time to reach the maximum concentration after drug administration (Tmax)

    Time frame: Week 8 - 12

  6. Pharmacokinetic comparability after the last dose - T1/2

    The terminal elimination half-life (T1/2)

    Time frame: Week 8 - 12

  7. Pharmacokinetic comparability at the end of each dosing interval - Ctrough

    Observed minimum serum ianalumab concentration following drug administration (Ctrough)

    Time frame: Week 0 - 12

  8. Pharmacodynamic effect as measured by B-cell level

    Circulating B cells (CD19+)

    Time frame: Week 0 - 112

  9. Immunogenicity as measured by Anti-Drug Antibodies

    Anti-ianalumab antibodies (ADA); incidence of ADA positive patients and correlation with AEs, PK and clinical outcomes

    Time frame: Week 0 - 112

07

Study locations

2 sites
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Amman, 11941, Jordan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2024, 66 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 66 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2018
First posted
Jul 2, 2018
StartActual
Dec 19, 2018
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03574545
Responsible party
Sponsor
First posted
Jul 2, 2018
Start date
Dec 19, 2018
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Last update
Dec 2, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion